(Q36133808)

12 August 2017

1 reference

title

Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders (English)

1 reference

12 August 2017

0 references

0 references

0 references

2

Lesley J Scott

1 reference

12 August 2017

M Asif A Siddiqui

1

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

65

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

1161-1177

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565080-00008

12 August 2017

exact match

0 references

cites work

Use of recombinant factor VIIa in surgery in factor-VII-deficient patients

1 reference

12 December 2020

Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders

1 reference

12 December 2020

Recombinant factor VIIa in joint and muscle bleeding episodes

1 reference

12 December 2020

Clinical experience with recombinant factor VIIa

1 reference

12 December 2020

Haemophilias A and B.

1 reference

12 December 2020

Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa

1 reference

12 December 2020

Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency.

1 reference

12 December 2020

Current concepts of hemostasis: implications for therapy.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

1 reference

12 December 2020

Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity--a rebuttal

1 reference

12 December 2020

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.

1 reference

12 December 2020

Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study

1 reference

12 December 2020

Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol.

1 reference

12 December 2020

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

1 reference

12 December 2020

The use of recombinant factor VIIa in the treatment of bleeding disorders.

1 reference

12 December 2020

A cell-based model of coagulation and the role of factor VIIa

1 reference

12 December 2020

Elective orthopedic surgery for hemophilia patients with inhibitors: New opportunities

1 reference

12 December 2020

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

1 reference

12 December 2020

Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.

1 reference

12 December 2020

NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds

1 reference

12 December 2020

Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay

1 reference

12 December 2020

Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.

1 reference

12 December 2020

The use of recombinant factor VIIa in children with inherited platelet function disorders

1 reference

12 December 2020

Overall experience with NovoSeven

1 reference

12 December 2020

Recombinant activated factor VII as a universal haemostatic agent

1 reference

12 December 2020

Factor VII deficiency

1 reference

12 December 2020

Treatment of the bleeding inhibitor patient

1 reference

12 December 2020

Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.

1 reference

12 December 2020

The European acquired haemophilia registry

1 reference

12 December 2020

The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study

1 reference

12 December 2020

Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors

1 reference

12 December 2020

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention

1 reference

12 December 2020

Recombinant factor VIIa (NovoSeven) as a hemostatic agent

1 reference

12 December 2020

Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors

1 reference

12 December 2020

Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies

1 reference

12 December 2020

Patient/caregiver assessment of convenience in the use of recombinant activated factor VII (rVIIa; NovoSeven) in home therapy

1 reference

12 December 2020

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

1 reference

12 December 2020

Recombinant factor VIIa does not induce hypercoagulability in vitro

1 reference

12 December 2020

Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program

1 reference

12 December 2020

How factor VIIa works in hemophilia

1 reference

12 December 2020

Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.

1 reference

12 December 2020

Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII.

1 reference

12 December 2020

Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia

1 reference

12 December 2020

Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors

1 reference

12 December 2020

Therapeutic choices for patients with hemophilia and high-titer inhibitors

1 reference

12 December 2020

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

1 reference

12 December 2020

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

1 reference

12 December 2020

Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.

1 reference

12 December 2020

Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.

1 reference

12 December 2020

Complications associated with the treatment of haemophiliacs with inhibitors

1 reference

12 December 2020

A Glanzmann's thrombasthenia cluster among Iraqi Jews in Israel

1 reference

12 December 2020

Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.

1 reference

12 December 2020

The 2000 United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) inhibitor guidelines

1 reference

12 December 2020

Recombinant Factor VIIa

1 reference

12 December 2020

A possible mechanism of action of activated factor VII independent of tissue factor

1 reference

12 December 2020

Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study

1 reference

12 December 2020

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

1 reference

12 December 2020

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

1 reference

12 December 2020

Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation

1 reference

12 December 2020

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery

1 reference

12 December 2020

Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response

1 reference

12 December 2020

A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors

1 reference

12 December 2020

Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment

1 reference

12 December 2020

Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency

1 reference

12 December 2020

Use of recombinant factor VIIa in hereditary bleeding disorders

1 reference

12 December 2020

Approaches towards successful home treatment in patients with inhibitors.

1 reference

12 December 2020

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.

1 reference

12 December 2020

Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia

1 reference

12 December 2020

ABC of clinical haematology. Bleeding disorders, thrombosis, and anticoagulation

1 reference

12 December 2020

Recombinant factor VIIa: a viewpoint by Jeanne M. Lusher

1 reference

12 December 2020

Prophylactic effect of recombinant factor VIIa in factor VII deficient patients.

1 reference

12 December 2020

Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders

1 reference

12 December 2020

Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII.

1 reference

12 December 2020

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity--a rebuttal.

1 reference

12 December 2020

Glanzmann's thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism

1 reference

12 December 2020

Mechanism of factor VIIa-dependent coagulation in hemophilia blood

1 reference

12 December 2020

The hemophilias--from royal genes to gene therapy

1 reference

12 December 2020

10.2165/00003495-200565080-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1037929350

0 references

1 reference